Dr. David L. Johnson, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
124 Sunset Court
West Columbia, SC 29169
Who else practices at this address →
Lexington County includes mental health (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of South Carolina School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 803
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of South Carolina School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
SC license MD23958 -
Ophthalmology Physician
WI license 48980
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Health Columbia Medical Center Downtown Columbia, SC
Medical groups
- Palmetto Retina Center LLC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 803
- Services billed
- 15,436
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, aflibercept, 1 mg | 3,200 | 259 |
| Imaging of retina | 2,440 | 778 |
| Injection of drug into eye | 1,614 | 323 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 944 | 40 |
| Established patient problem focused exam of visual system | 867 | 394 |
| Injection, ranibizumab, 0.1 mg | 600 | 45 |
| Established patient complete exam of visual system | 548 | 411 |
| New patient office or other outpatient visit, 45-59 minutes | 196 | 196 |
| Unclassified drugs | 46 | 24 |
| 2d ultrasound scan of eye tissue and structures | 25 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in West Columbia, SC | 96 |
| Ofloxacin Other prescribers in West Columbia, SC | 42 |
| Atropine Sulfate | 34 |
| Ketorolac Tromethamine Other prescribers in West Columbia, SC | 24 |
| Timolol Maleate Other prescribers in West Columbia, SC | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $157 in total to this clinician.
| Genentech USA, Inc. | $37.55 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $34.60 |
| Astellas Pharma US Inc | $32.23 |
| Boston Scientific Corporation | $28.09 |
| AbbVie Inc. | $24.41 |
| Food and Beverage | $157 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $1,302,778 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.